ERBB2 and neoplasm: The addition of the anti-PD-1 agent to chemotherapy and trastuzumab, for HER2-positive metastatic gastroesophageal adenocarcinoma in the phase III Keynote 811 study resulted in a significant improvement of tumor response rate.